Maximum yields of 1,250 IU (international unit) /g (dry weight of cells) of L-asparaginase were obtained in 8 hr from Erwinia aroideae NRRL B-138. Partial purification and concentration of the extracted L-asparaginase yielded a preparation with an activity of 275 IU/ml. Only one L-asparaginase was present as determined by electrophoresis, and the enzyme exhibited a pH optimum of 7.5 and a Km of 3 X Io-M. L-Asparaginase is an effective antileukemia agent in mice and rats (2, 4, 7) . Current clinical studies indicate that this enzyme is also a promising agent in treating some forms of neoplastic cell disease in man (9). At present, the principal source of L-asparaginase for clinical trials is the bacterium Escherichia coli (1). Although production and purification techniques have been developed, they generally provide a quantity of enzyme sufficient for only limited trials. Possibly, alternative sources of L-asparaginase could overcome the problem of antigenic reactions found in some patients (9).
Maximum yields of 1,250 IU (international unit) /g (dry weight of cells) of L-asparaginase were obtained in 8 hr from Erwinia aroideae NRRL B-138. Partial purification and concentration of the extracted L-asparaginase yielded a preparation with an activity of 275 IU/ml. Only one L-asparaginase was present as determined by electrophoresis, and the enzyme exhibited a pH optimum of 7.5 and a Km of 3 X Io-M.
L-Asparaginase is an effective antileukemia agent in mice and rats (2, 4, 7) . Current clinical studies indicate that this enzyme is also a promising agent in treating some forms of neoplastic cell disease in man (9) . At present, the principal source of L-asparaginase for clinical trials is the bacterium Escherichia coli (1) . Although production and purification techniques have been developed, they generally provide a quantity of enzyme sufficient for only limited trials. Possibly, alternative sources of L-asparaginase could overcome the problem of antigenic reactions found in some patients (9) .
A screen of microorganisms in the Agricultural Research Service Culture Collection at the Northern Laboratory has shown that some bacteria produce larger quantities of L-asparaginase than E. coli (10) . Of these, Erwinia aroideae (Townsend) Holland NRRL B-138 was selected for further study. In addition, extraction procedures were investigated to determine which would liberate the maximum amount of L-asparaginase from the cells. Partial purification techniques were utilized to furnish a product suitable for preliminary antitumor trials in mice.
MATERIALS AND METHODS Enzyme production. E. aroideae NRRL B-138 was used throughout this investigation. The Growth studies. Fernbach flasks, prepared as above, were sampled (5-ml samples) at 1-hr intervals. Determinations were made for pH, protein concentration, cell count, and L-asparaginase activity.
Production studies. In semipilot-plant trials, 20-liter stainless-steel fermentors were utilized (3). Temperature was held at 28 C, and aeration rates were varied to determine the effect on cell growth and L-asparaginase yield. Cells were harvested after 24 hr by centrifugation and washed with phosphate buffer (Na2HPO4, 4.76 g; KH2PO4, 4.54 g; Triton X-100, 0.125 ml; distilled water to 1 liter; pH adjusted to 7.0).
Extraction procedures. Lysozyme spheroplast formation with subsequent release of L-asparaginase was carried out by the method of Malamy and Horecker (6) . Washed cells (300 g) were suspended in 2 liters of 20% sucrose-0.033 M tris(hydroxymethyl)aminomethane (Tris) buffer, pH 8.0. Successive treatments of the cells with 0.01 volume of 0.1 M ethylenediaminetetraacetic acid, pH 8.0, and 10 pliters of lysozyme (5 mg/ml) per ml of suspension were performed at 5 C. The suspension was stirred gently, and osmotic fragility was checked at 15-min intervals by determining the optical density (OD) at 490 nm. After the decrease in OD had ceased, the suspension was centrifuged at 13,000 X g for 2 hr. To analyze for efficiency of extraction, the spheroplasts were resuspended in 2 liters of the original sucrose-Tris solution. Analyses for enzyme content were made on the resuspended spheroplasts and on the supernatant fluid from the final centrifugation.
Purification procedures. All purification steps were carried out at 4 C. Supernatant fluid from the extraction procedure was treated with 0.05-volumes of 1.0 M MnCl2 to partially remove nucleic acid. After the MnCl2 was added, the suspension was stirred for 1 hr, allowed to stand for 15 min, and then centrifuged to remove precipitate. The 1, 250 IU/g (dry weight) of cells. On longer incubation, the wet-cell weight per milliliter and the L-asparaginase concentration appeared to remain constant from 11 to 24 hr. The pH dropped to a minimum of 6.8 at 3 hr and then increased in most experiments to a maximum of 8.5. Enzyme production began just before the upward trend of the pH curve.
Aeration was varied in 24-hr production runs in 20-liter fermentors (Table 1 ). Higher aeration rates produced greater cell production; however, total L-asparaginase production was lowered 70%c.
Harvest and extrcion. Asparagnase activity was completely intracellular during the growth (Fig. 2) , electrophoretic studies (Fig. 3) , and Lineweaver-Burk data for Km calculation (Fig. 4) IU of this L-asparaginase. Within 4 days, tumor regression averaged 6 mm. A single dose of 5 IU injected intraperitoneally into each of three mice was sufficient to cause complete remission of the implanted tumors. In later tests, an enzyme solution exhibited some toxicity. This toxicity, which appeared in only some of the test animals, was probably caused by proteinaceous material other than the L-asparaginase present in the partially purified extracts. Indications are that increased purification would give a relatively nontoxic product suitable for intensive animal testing.
Alternative sources of enzyme to that now in therapeutic use are desirable in treatment of human neoplasia to overcome the problem of antigenic reactions. E. aroideae lends itself to large-scale production of L-asparaginase for human antitumor therapy. High yields in short growth periods should make available greater quantities of this enzyme.
